What is Northland Capmk's Forecast for BLFS Q3 Earnings?

BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Investment analysts at Northland Capmk issued their Q3 2025 earnings per share (EPS) estimates for shares of BioLife Solutions in a report issued on Friday, May 9th. Northland Capmk analyst C. Byrnes expects that the medical equipment provider will earn ($0.01) per share for the quarter. The consensus estimate for BioLife Solutions' current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions' Q4 2025 earnings at $0.00 EPS.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The company had revenue of $23.94 million during the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%.

Other research analysts have also issued reports about the company. StockNews.com raised BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of "Moderate Buy" and a consensus price target of $31.17.

BioLife Solutions Stock Down 4.5%

BLFS stock traded down $1.04 during mid-day trading on Monday, hitting $22.05. The stock had a trading volume of 725,410 shares, compared to its average volume of 382,044. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a 1-year low of $18.70 and a 1-year high of $29.55. The company has a fifty day moving average of $23.71 and a 200 day moving average of $25.31. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -20.80 and a beta of 2.01.

Insider Buying and Selling

In other news, CFO Troy Wichterman sold 4,151 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $103,775.00. Following the sale, the chief financial officer now owns 116,809 shares in the company, valued at approximately $2,920,225. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Aby J. Mathew sold 10,589 shares of the firm's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $239,946.74. Following the completion of the sale, the executive vice president now owns 309,576 shares in the company, valued at approximately $7,014,992.16. The trade was a 3.31% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,696 shares of company stock worth $1,665,094. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BLFS. Steward Partners Investment Advisory LLC acquired a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $31,000. US Bancorp DE grew its holdings in shares of BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 1,528 shares in the last quarter. 1620 Investment Advisors Inc. grew its holdings in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 675 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of BioLife Solutions by 18.6% during the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after purchasing an additional 663 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.